Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 3, 2024
Daily News
June 3, 2024
- Janssen Files Amivantamab for Post-Tagrisso NSCLC Setting in Japan
June 3, 2024
- Bayer, Kyoto University Form Strategic Alliance to Fuel Innovation
June 3, 2024
- Tapinarof Cream Hits Main Goal in PIII Eczema Trial in Children: JT/Torii
June 3, 2024
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…